Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
Public ClinicalTrials.gov record NCT01543919. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Obstructive Pulmonary Disease (COPD)
Study identification
- NCT ID
- NCT01543919
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 730 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2012 (Type not available)
- Primary completion
- Sep 2013 (Actual)
- Completion
- Sep 2013 (Actual)
- Last update posted
- Oct 27, 2014
2012 – 2013
United States locations
- U.S. sites
- 45
- U.S. states
- 22
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35205 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Jasper | Alabama | 35501 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Montclair | California | 91763 | — |
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | Newark | Delaware | 19713 | — |
| Pfizer Investigational Site | Brandon | Florida | 33511 | — |
| Pfizer Investigational Site | Chiefland | Florida | 32226 | — |
| Pfizer Investigational Site | Chiefland | Florida | 32626 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33756 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33765 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34653 | — |
| Pfizer Investigational Site | Pensacola | Florida | 32504 | — |
| Pfizer Investigational Site | Tampa | Florida | 33603 | — |
| Pfizer Investigational Site | Williston | Florida | 32696 | — |
| Pfizer Investigational Site | Duluth | Georgia | 30096 | — |
| Pfizer Investigational Site | Fort Mitchell | Kentucky | 41017 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40504 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21224 | — |
| Pfizer Investigational Site | Edina | Minnesota | 55435 | — |
| Pfizer Investigational Site | Fridley | Minnesota | 55432 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55407 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87108 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87109 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87110 | — |
| Pfizer Investigational Site | Rochester | New York | 14618 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28207 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45231 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45242 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45245 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| Pfizer Investigational Site | Pawtucket | Rhode Island | 02860 | — |
| Pfizer Investigational Site | Warwick | Rhode Island | 02886 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29407 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29414 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78212 | — |
| Pfizer Investigational Site | Midvale | Utah | 84047 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01543919, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2014 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01543919 live on ClinicalTrials.gov.